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Proof That Lower Is Better — LDL Cholesterol 
and IMPROVE-IT
John A. Jarcho, M.D., and John F. Keaney, Jr., M.D.
The so-called LDL hypothesis is the concept that 
excess low-density lipoprotein (LDL) cholesterol 
is a causal factor in the development of athero-
sclerotic vascular disease. By extension, this 
hypothesis also assumes that reducing LDL cho-
lesterol levels, regardless of the means, should 
produce a corresponding reduction in cardiovas-
cular events. Considerable evidence supports the 
LDL hypothesis, including animal studies and 
epidemiologic studies involving humans, as well 
as clinical trials of both statins and nonstatin 
lipid-modifying agents. In a meta-analysis that 
included more than 90,000 participants in 14 ran-
domized trials of statins, the Cholesterol Treat-
ment Trialists’ (CTT) collaborators found that, on 
average, a reduction of 1 mmol per liter (38.7 mg 
per deciliter) in LDL cholesterol levels yields a 
consistent 23% reduction in the risk of major 
coronary events over 5 years.1
Despite this body of evidence, there has been 
a long-standing argument that the beneficial ef-
fects of statins are not adequately explained by 
their effects on LDL cholesterol. Statins have a 
complex array of biologic effects — including 
amelioration of endothelial dysfunction, increased 
nitric oxide bioavailability, antioxidant properties, 
and inhibition of inflammation — that are un-
related to their lipid-lowering effect and that are 
sometimes called “pleiotropic effects.”2 It has 
been argued that such effects may account for at 
least some of the benefit of statin therapy in 
preventing cardiovascular events. This alterna-
tive theory is sometimes referred to as the 
“statin hypothesis” — the idea that statins have 
a unique efficacy in atherosclerotic vascular dis-
ease that is not shared by other lipid-modifying 
agents and that reduction in LDL cholesterol 
levels is not the only basis for the beneficial ef-
fect of statins (Fig. 1).
Several recent negative clinical trials have 
seemed to offer support for the statin hypothe-
sis. In each of these trials, the addition of a 
nonstatin lipid-modifying agent to statin therapy 
conferred no significant increment in cardiovas-
cular benefit over that seen with a statin alone.3-6 
In addition, in a clinical trial of rosuvastatin,7 
the beneficial effect of this statin was found to 
correlate not only with its effect on LDL choles-
terol levels but also independently with its ability 
to reduce the level of high-sensitivity C-reactive 
protein, a marker of inflammation.8 Given these 
findings, the 2013 cholesterol treatment guide-
lines of the American College of Cardiology and 
the American Heart Association heavily empha-
sized statin therapy as the preferred treatment 
option for patients with established cardiovascu-
lar disease or hyperlipidemia.9
With this background, the report by Cannon 
et al. of the Improved Reduction of Outcomes: 
Vytorin Efficacy International Trial (IMPROVE-IT),10 
now published in the Journal, offers important 
new evidence in favor of the LDL hypothesis. In 
IMPROVE-IT, 18,144 patients who had had an 
acute coronary syndrome were randomly as-
signed to either simvastatin (40 mg) plus ezeti-
mibe (10 mg) or to simvastatin (40 mg) plus 
placebo. At 1 year, the mean LDL cholesterol level 
was 53.2 mg per deciliter (1.4 mmol per liter) in 
the simvastatin-plus-ezetimibe group, and 69.9 mg 
per deciliter (1.8 mmol per liter) in the simvas-
tatin-monotherapy group. The primary end point 
was a composite of cardiovascular death, major 
coronary event (nonfatal myocardial infarction, 
unstable angina, or coronary revascularization), 
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or nonfatal stroke. At 7 years, the rate of the 
primary end point was significantly lower, by 
2.0 percentage points, in the simvastatin-plus-
ezetimibe group than in the simvastatin-mono-
therapy group (32.7% vs. 34.7%). No significant 
differences in rates of adverse events were seen 
between the two study groups.
IMPROVE-IT is a landmark study in that it is 
the first clinical trial to show a benefit of adding 
a nonstatin lipid-modifying agent to statin ther-
apy. Ezetimibe, the added agent in this trial, 
works by reducing the intestinal absorption of 
cholesterol, a distinct mechanism that is unre-
lated to that of statins. And yet, the event-rate 
reduction with the addition of ezetimibe was 
precisely the same as that predicted by the CTT 
analysis of statin trials described above (see 
Fig. 2 in the article by Cannon et al.),10 which 
suggests that reduction of LDL cholesterol levels 
per se explains the effect of statins on coronary 
heart disease.
These results offer important hope to patients 
who have unacceptable side effects from statin 
therapy and to those who may not achieve ade-
quate LDL reduction with statins. The 2013 
guidelines do not recommend the use of spe-
cific targets for LDL cholesterol levels, but they 
do acknowledge that some patients may have an 
“insufficient response to statin therapy” and 
that in such patients the addition of a nonstatin 
agent may be considered.9 The results of 
 IMPROVE-IT should, at a minimum, reinforce 
such a recommendation and will undoubtedly 
rekindle arguments in favor of targets for LDL 
cholesterol levels.
The results of IMPROVE-IT also imply that 
other interventions to reduce LDL cholesterol 
levels may prove to be beneficial. In this regard, 
the recent development of PCSK9 inhibitors is of 
note. These agents reduce LDL-receptor degrada-
tion, thereby enhancing LDL clearance from the 
circulation, and they have been shown to reduce 
LDL cholesterol levels by as much as 60%.11,12
Definitive clinical outcomes trials with these 
agents are ongoing.
IMPROVE-IT should not be interpreted as 
showing anything uniquely beneficial about the 
use of ezetimibe. Indeed, the real implication of 
IMPROVE-IT is to suggest that all reductions in 
LDL levels, regardless of mechanism, are of 
equivalent benefit. Thus, a patient who is cur-
rently being treated with 40 mg of simvastatin 
would be expected to benefit just as much from a 
higher-intensity statin regimen (e.g., 40 to 80 mg 
of atorvastatin or 20 to 40 mg of rosuvastatin) as 
from the addition of ezetimibe, assuming equiv-
alent reductions in LDL cholesterol levels.
A sobering observation was that 42% of the 
participants in IMPROVE-IT, regardless of treat-
ment assignment, discontinued the study medi-
cation prematurely. As noted by the authors, this 
discontinuation rate is approximately 7% per year, 
which closely mirrors that seen in other trials. 
Since lipid-lowering is presumably intended to 
be a lifelong goal, this diminishment in long-
term use is an important practical clinical con-
cern, and one that suggests that treatment ad-
herence to lipid-lowering therapy needs to be an 
ongoing focus of practitioner attention. It also 
raises questions about the practicality of long-
term use of PCSK9 inhibitors, since all these 
agents are currently given by subcutaneous in-
jection once every 2 to 4 weeks.
Overall, IMPROVE-IT provides us with impor-
tant information on the value of lowering LDL 
cholesterol levels, regardless of the agent used. 
These data help emphasize the primacy of LDL 
cholesterol lowering as a strategy to prevent coro-
nary heart disease. Perhaps the LDL hypothesis 
should now be considered the “LDL principle.”
Figure 1. Schematic Depiction of the Statin Hypothesis.
The reduction in low-density lipoprotein (LDL) choles-
terol with lipid-modifying agents is plotted against the 
reduction in cardiovascular events under either the LDL 
hypothesis or the statin hypothesis. The putative add-
ed “pleiotropic” effects of statins (effects that are un-
related to their lipid-lowering effects) are represented 
by the shaded area. The IMPROVE-IT trial provides im-
portant new evidence in favor of the LDL hypothesis.
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Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
From the University of Massachusetts Medical School, Worces-
ter, MA (J.F.K.). 
This article was published on June 3, 2015, at NEJM.org.
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